What a Difference 10 Years Can Make
2023; Elsevier BV; Volume: 11; Issue: 1 Linguagem: Inglês
10.1016/j.jaip.2022.10.028
ISSN2213-2201
AutoresDawn Angel, Michael Schätz, Robert S. Zeiger, Scott H. Sicherer, David A. Khan,
Tópico(s)IL-33, ST2, and ILC Pathways
ResumoThink back. What were you doing 10 years ago? It was 2013. The Baltimore Ravens won the Super Bowl, the World Baseball Classic was won by the undefeated Dominican Republic, Adam Scott was the first Australian to win the Masters, the Kentucky Derby winner was Orb, the Miami Heat secured the US National Basketball Association Finals, Chicago’s Blackhawks won the Stanley Cup, Wimbledon singles winners were Andy Murray and Marion Bartoli, Chris Froome rode to the finish line first in the Tour de France, the Boston Red Sox hit it out of the park in the World Series, Bayern München prevailed in the FIFA World Cup,1Wood Robert World Sports Highlights. Topend Sports, 2013https://www.topendsports.com/world/timeline/2013.htmDate accessed: October 12, 2022Google Scholar and, outside the world of sports, The Journal of Allergy and Clinical Immunology (JACI): In Practice published our inaugural issue. Fast forward 10 years, we have published 78 issues and five supplements, with a total of over 20,000 pages of content. And the editorial team has had a ball developing a journal that we hope our readers think is a winner! In July 2012, JACI: In Practice’s submissions site (https://www.editorialmanager.com/inpractice) officially opened, and we began collecting manuscripts for review. One hundred and one submissions were received in 2012, and we collected over 1,700 submissions last year (Figure 1). We obtained nearly 2,700 reviews last year compared with 200 reviews in that first year (Figure 1). Our inaugural issue, January/February 2013, was 108 pages, and a total of 708 pages were printed in 2013. This is compared with the January 2022 issue of 358 pages and a total of 3,348 pages in all of 2022. (Figure 1). We are extremely proud of the progress we have made since our inception, going from no Clarivate impact factor (IF) to our first IF of 5.429 (awarded in 2015) and to our current, thrilling 11.022 IF (Figure 2). Our total citations have risen exponentially (Figure 3), while our downloads and website visits have also grown substantially (Figure 4). We believe that all of this reflects that we are fulfilling our mission of providing novel, valid, generalizable, and impactful information to support evidence-based clinical decisions in the diagnosis and management of asthma, allergic, immunologic, and related conditions.Figure 3The number of issues and supplements The Journal of Allergy and Clinical Immunology: In Practice has published so far, the number of podcasts we have released, the total number of article continuing medical education credits awarded since our first issue of publication, the total citations we have received since 2015 (tracked with our impact factor, which was awarded in 2015), our average time from submission to first decision, and the total visitors to our website in 2021.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 4Full-text use of The Journal of Allergy and Clinical Immunology: In Practice articles across three platforms: ScienceDirect (SD), our own journal site (jaci-inpractice.org) (JBS), and ClinicalKey (CK). These show the total HTML views and PDF article downloads from all three resources.View Large Image Figure ViewerDownload Hi-res image Download (PPT) One aspect of our journal about which we are extremely proud is the number and quality of the resources we provide beyond our articles (Figure 3). We offer multiple ways to claim continuing medical education (CME) credits (https://www.jaci-inpractice.org/cme-resources), including from select review articles (typically three in each issue), credit for reviewing, and our Virtual Journal Club (VJC [https://www.jaci-inpractice.org/virtual-journal-club]). In conjunction with the New Allergist/Immunologist Assembly, the VJC is a quarterly webinar discussing two JACI: In Practice articles. This is recorded, and both the live event and recordings are available for CME (Figure 3). In mid-2020, we started a podcast (https://www.jaci-inpractice.org/content/podcast). JACI: In Practice Issue Highlights is released each month and describes the issue in 20 to 30 minutes. The podcasts are available wherever you stream your favorite music. On our website, we host the Question of the Month, a multiple choice question based on one of our theme review articles. In addition, our editors put together a set of Year in Review slides summarizing our most important articles on key allergy/immunology topics: Asthma, Food Allergy and Anaphylaxis, and Drug Allergy and Urticaria/Angioedema (https://www.jaci-inpractice.org/key-allergy-immunology-topics). These slides are updated annually. For our reviewers, we offer several benefits (https://www.jaci-inpractice.org/content/information-for-reviewers). Reviewers can earn CME credit (up to 15 credits/y) for reviews. We have partnered with our sister journals, JACI and JACI: Global, and the American Academy of Allergy, Asthma & Immunology (AAAAI) Program Directors Assembly on the Fellows in Training (FIT)/Faculty Reviewer Program to facilitate faculty mentorship in assisting FITs in learning how to review for scientific journals. Moreover, we award five reviewers each year with our Outstanding Reviewer Award, which is given for excellence and quality in reviews. If you are interested in joining our reviewer family, please contact us at [email protected]. We are pleased to be working toward several initiatives to increase our diversity, equality, and inclusion (https://www.jaci-inpractice.org/content/dei-initiatives). In 2021, Dr Bridgette Jones, MD, MS, was appointed to the editorial board as our diversity, equality, and inclusion coordinator to help us organize and enhance our efforts. In the past year, we have also updated our guidelines on reporting race, ethnicity, sex, and gender; added a new Case Studies in Health Disparities article type; and added a Health Disparities Collection on our website, which gathers all In Practice articles in this topic in one place.2Angel D.M. Schatz M. Zeiger R.S. Sicherer S.H. Khan D.A. Diversity, equity, and inclusion: what can a journal do?.J Allergy Clin Immunol Pract. 2021; 9: 3853-3856Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar We have also issued an AAAAI Journals Diversity Statement with our sister journals. Submissions as well as our reviewers have diversified over the past 10 years: we have received submissions from 89 countries (see Table E1 in this article’s Online Repository at www.jaci-inpractice.org) and reviews from 53 countries (see Table E2 in this article’s Online Repository at www.jaci-inpractice.org). We will continue to track these data and further expand our reach across the globe. Over the past 10 years, the Journal has attempted to publish clinically impactful articles on the spectrum of conditions treated by allergist-immunologists in their practice: food allergy, respiratory disorders (including asthma, allergic and nonallergic rhinitis/rhinoconjunctivitis, nasal polyps, chronic sinusitis, cough, allergic bronchopulmonary aspergillosis, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (including atopic dermatitis, contact dermatitis, urticaria, angioedema, and hereditary angioedema), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders. To celebrate our 10 years of publication, we have asked our current editorial board members to write review articles on most of these topics for this anniversary issue.3Ponda P. Carr T. Rank M.A. Bousquet J. Rhinitis, non-allergic rhinitis and immunotherapy: advances in the last decade.J Allergy Clin Immunol Pract. 2023; 11: 35-42Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar, 4Weiler C.R. Schrijvers R. Golden D.B.k. Anaphylaxis: Advances in the Past 10 Years.J Allergy Clin Immunol Pract. 2023; 11: 51-62Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar, 5Pavord I. Barnes P.J. Lemiere C. Gibson P.G. Diagnosis and assessment of the asthmas.J Allergy Clin Immunol Pract. 2023; 11: 1-8Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar, 6Busse W.W. Castro M. Casale T.B. Asthma management in adults.J Allergy Clin Immunol Pract. 2023; 11: 21-33Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar, 7Shipp C, Gergen PJ, Gern JE, Matsui EC, Guilbert T. Asthma management in children. J Allergy Clin Immunol Pract 2023;11:9-18.Google Scholar, 8Arkwright P.D. Koplin J.J. Impact of a decade of research into atopic dermatitis.J Allergy Clin Immunol Pract. 2023; 11: 63-71Abstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar, 9Naclerio R. Mullol J. Stevens W.W. A decade of clinical advances in chronic rhinosinusitis: 2012.J Allergy Clin Immunol Pract. 2023; 11: 43-50Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar, 10Macy E. Trautmann A. Chiriac A.M. Demoly P. Phillips E.J. Advances in the understanding of drug hypersensitivity: 2012 through 2022.J Allergy Clin Immunol Pract. 2023; 11: 80-91Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar, 11Turner PJ, Tang MLK and Wood RA. Food allergy and eosinophilic gastrointestinal diseases: The next 10 years. J Allergy Clin Immunol Pract 2023;11:72-78.Google Scholar, 12Walter JE, Ziegler JB, Ballow M, Cunningham-Rundles C. Advances and challenges of the decade: the ever-changing clinical and genetic landscape of immunodeficiency. J Allergy Clin Immunol Pract 2023;11:107-115.Google Scholar, 13Konstantinou GN, Reidl MA, Valent P, Podder I, Maurer M. Urticaria and angioedema: Understanding complex pathomechanisms to facilitate patient communication, disease management, and future treatment. J Allergy Clin Immunol Pract 2023;11:94-106.Google Scholar In addition to articles on specific conditions, we have included articles on the timely topics of diversity, equity, and inclusion14Jones B. Carter M.C. Davis C.M. Wang J. Diversity, equity, and inclusion: a decade of progress?.J Allergy Clin Immunol Pract. 2023; 11: 116-125Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar; teleallergy15Ramsey A. Wu A.C. Bender B.G. Portnoy J. Teleallergy: where have we been and where are we going.J Allergy Clin Immunol Pract. 2023; 11: 126-131Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar; and value-based cost-effective care.16Shaker M. Mauger D. Fuhlbrigge A.L. Value-based, cost-effective care: the role of the allergist/immunologist.J Allergy Clin Immunol Pract. 2023; 11: 132-139Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar We hope you agree that these state-of-the-art articles written by true experts in their fields are a fitting way to celebrate the clinical resource mission of our journal. There is an African proverb that it takes a village to raise a child. It also takes a village to raise a new journal. Before we conclude this editorial, we want to thank that village. To begin, we thank all of the many worldwide authors who have chosen to publish their articles with us over this past decade, without whom, of course, there would be no journal. Thanks also go to our more than 1,200 reviewers whose volunteered time and expertise have helped us not only to determine what articles are novel, valid, generalizable, and clinically impactful enough to warrant publication in the Journal, but also to help make those articles the best they can be. We are extremely appreciative of our past and present esteemed editorial board members (Table I), who have provided so many contributions to the Journal, including their multiple excellent article reviews, coordination of our signature theme issues, and invaluable guidance regarding Journal content and policies. We could not be where we are today without the unwavering support of the AAAAI Board of Directors over these past 10 years, and we are particularly appreciative of the wise counsel and advice we receive from our journal liaison, AAAAI Executive Director Rebecca Brandt. We also would not have a journal without a publisher, and Elsevier has filled that role terrifically. We particularly thank their publisher representatives, starting with Terrie Duhadway for more than half of our life span, then Mary Ann Zimmerman, and now Rachael Engels, all of whom have been extremely helpful in so many aspects of our journal functioning. Finally, we thank you, our readers and your patients, who provide the inspiration for what we do. For more gratitude, stay tuned for our February, March, and July issues, in which we will publish our annual Thank You lists of our Virtual Journal Club presenters, our reviewers, and participants in our FIT/Faculty Reviewer Program, respectively.Table IThe Journal of Allergy and Clinical Immunology: In Practice editorial board members over the past 10 y and their locations at the time they servedRob C. AalberseAmsterdamThe NetherlandsPeter D. ArkwrightManchesterUnited KingdomLuisa Karla ArrudaRibeirão PretoBrazilLeonard B. BacharierSt LouisMoUSAMark BallowSarasotaFlaUSAPeter J. BarnesLondonUnited KingdomBruce G. BenderDenverColoUSADavid I. BernsteinCincinnatiOhioUSACarsten Bindslev-JensenOdenseDenmarkBengt BjorkstenStockholmSwedenKimberly Gold BlumenthalBostonMassUSAMark BoguniewiczDenverColoUSASergio BoniniRomeItalyJean BousquetMontpellierFranceA. Wesley BurksChapel HillNCUSAWilliam W. BusseMadison WisUSAMoisés A. CalderónLondonUnited KingdomTara F. CarrTucsonArizUSAMelody C. CarterBethesdaMdUSAThomas B. CasaleTampa FlaUSAMariana C. CastellsBostonMassUSAMario CastroOverland ParkKanUSAAnca Mirela ChiriacMontpellierFranceJohn R. CohnPhiladelphiaPennUSALinda S. CoxFt. LauderdaleFlaUSACharlotte Cunningham-RundlesNew YorkNYUSACarla M. DavisHoustonTexasUSAPascal DemolyMontpellierFranceSten DreborgUppsalaSwedenMotohiro EbisawaSagamiharaJapanAnne M. FitzpatrickAtlantaGaUSAAnne L. FuhlbriggeAuroraColoUSAPeter J. GergenBethesdaMdUSAJames E. GernMadisonWisUSAPeter GibsonNewcastleAustraliaDavid B.K. GoldenBaltimoreMdUSALeslie C. GrammerChicagoIllUSAPaul A. GreenbergerChicagoIllUSATheresa W. GuilbertCincinnatiOhioUSARobert G. HamiltonBaltimoreMdUSAGünther F.L. HofbauerZurichSwitzerlandMary Beth HoganLas VegasNevUSADavid P. HustonHoustonTexasUSACharles IrvinColchesterVtUSAElliot IsraelBostonMassUSABridgette L. JonesKansas CityMissUSACorinne KeetBaltimoreMdUSAKevin J. KellyChapel HillNCUSAJohn M. KelsoSan DiegoCalifUSADavid A. KhanDallasTexasUSAGeorge KonstantinouThessalonikiGreeceJennifer KoplinParkvilleAustraliaGideon LackLondonUnited KingdomDennis K. LedfordTampaFlaUSACatherine LemiereMontrealCanadaJames T. LiRochesterMinnUSARichard F. LockeyTampaFlaUSAEric M. MacySan DiegoCalifUSAFernando D. MartinezTucsonArizUSAElizabeth C. MatsuiAustinTexasUSADavid T. MaugerHersheyPennUSAMarcus MaurerBerlinGermanyJoaquim MullolBarcelonaCataloniaSpainRobert M. NaclerioBaltimore MdUSAGiovanni PassalacquaGenoaItalyIan D. PavordOxfordUnited KingdomStephen P. PetersWinston-SalemNCUSAElizabeth J. PhillipsNashvilleTennUSAWanda PhipatanakulBostonMassUSAThomas A.E. Platts-MillsCharlottesvilleVaUSAPunita PondaGreat NeckNYUSAJay M. PortnoyKansas CityMissUSARima A. RachidBostonMassUSAAllison RamseyRochesterNYUSAMatthew A. RankScottsdaleArizUSAMarc A. RiedlLa JollaCalifUSAVito SabatoEdegemBelgiumHugh A. SampsonNew YorkNYUSARik SchrijversLeuvenBelgiumBrian C. SchroerClevelandOhioUSAMarcus S. ShakerLebanonNHUSARoland SolenskyCorvallisOreUSAWhitney StevensChicagoIllUSAMimi L.K. TangParkvilleAustraliaWinnie TongSydneyAustraliaAxel TrautmannWürzburgGermanyPaul J. TurnerLondonUnited KingdomPeter ValentWienAustriaErika von MutiusMunichGermanyJolan E. WalterSt. PetersburgFlaUSAJulie WangNew YorkNYUSARichard L. WassermanDallasTexasUSACatherine WeilerRochester MinnUSARobert A. WoodBaltimoreMdUSAAnn Chen WuBostonMassUSAJohn B. ZieglerSydneyAustralia Open table in a new tab For the past 10 years, we have been guided by our articulated vision to be an indispensable resource for clinicians who manage patients with asthma, allergic, immunologic, and related conditions to optimize the care and health of these patients. As we move into our second decade, we pledge to continue to pursue that goal avidly, supported by our village, and hope to make an ever-increasing impact on the world of allergy/immunology and on the lives of our clinician readers and their patients. Table E1Countries from which JACI: In Practice has received submissions (based on the corresponding author’s country of residence).Corresponding author’s country of residenceAlbaniaArgentinaAustraliaAustriaBahrainBelgiumBrazilBulgariaCameroonCanadaChileChinaColombiaCosta RicaCroatiaCyprusCzech RepublicCzechiaDenmarkEcuadorEgyptEthiopiaFinlandFranceGermanyGreeceHoly See (Vatican City State)Hong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsraelItalyJapanJordanKenyaKorea, Republic ofKuwaitLebanonLithuaniaLuxembourgMacaoMacauMalaysiaMaltaMexicoMonacoMoroccoNetherlandsNew ZealandNigerNorwayOmanPalestinian Territory, OccupiedPeruPhilippinesPolandPortugalPuerto RicoQatarRomaniaRussian FederationSaudi ArabiaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSpainSri LankaSwedenSwitzerlandSyrian Arab RepublicTaiwanTaiwan, Province of ChinaThailandTunisiaTurkeyUnited Arab EmiratesUnited KingdomUnited StatesVenezuelaViet Nam Open table in a new tab Table E2Countries of residence of JACI: In Practice reviewersReviewer’s country of residenceArgentinaAustraliaAustriaBelgiumBrazilCanadaChileChinaColombiaCroatiaCyprusCzech RepublicDenmarkEgyptEstoniaFinlandFranceGermanyGreeceHoly See (Vatican City State)Hong KongHungaryIndiaIndonesiaIran (Islamic Republic of)IrelandIsraelItalyJapanKorea, Republic ofLuxembourgMalaysiaMexicoNetherlandsNew ZealandNorwayPolandPortugalQatarRomaniaSerbiaSingaporeSouth AfricaSpainSwedenSwitzerlandTaiwanTaiwan, Province of ChinaThailandTurkeyUnited KingdomUnited StatesUruguayData are self-reported by each reviewer. Open table in a new tab Data are self-reported by each reviewer. Anaphylaxis: Advances in the Past 10 YearsThe Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewIn the past 10 years, anaphylaxis has grown into its own special area of study within Allergy-Immunology, both at the bench and at the bedside. This review focuses on some of the most clinically relevant advances over the past decade. These include simplified and more inclusive diagnostic criteria for adults and children, uniform definition of biphasic anaphylaxis, and improved systems for objective severity grading. Studies reported in the past decade have led to improved understanding of normal and abnormal regulation of mast cell function, translating into better diagnostic and therapeutic approaches to patients with anaphylaxis. Full-Text PDF Nonallergic Rhinitis, Allergic Rhinitis, and Immunotherapy: Advances in the Last DecadeThe Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewChronic rhinitis encompassing both allergic and nonallergic rhinitis affects a significant portion of the population worldwide, having a great impact on patient quality of life, and associated comorbid conditions, with an important societal economic burden. Allergists are often the first to evaluate and treat allergic and nonallergic rhinitis, addressing the individual triggers of the disease as well as the patient-specific responses to these triggers. This review focuses on the advances that have been made in the diagnosis, management, and treatment of nonallergic and allergic rhinitis over the past 10 years, including specific allergen immunotherapy, care pathways, and digital health. Full-Text PDF Impact of a Decade of Research Into Atopic DermatitisThe Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewThe last decade has seen an unprecedented pace of change, particularly of clinical research in atopic dermatitis (AD). This review summarizes some key discoveries. Over the last 10 years, nearly half of all studies investigated the efficacy and safety of novel therapeutic agents, particularly biologics and small molecules. Clear demonstration of benefit in clinical trials with no significant safety concerns provided strong evidence leading to subsequent Food and Drug Administration approval and routine use of the anti–IL-4 receptor alpha antagonist dupilumab in patients 6 months and older, the selective Janus kinase 1 (JAK1) inhibitors upadacitinib for patients 12 years and older and abrocitinib, the IL-13 antagonist tralokinumab, and the JAK1/2 inhibitor baricitinib for adults 18 years and older. Full-Text PDF Food Allergy and Eosinophilic Gastrointestinal Diseases—The Next 10 YearsThe Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewThe first report of food allergy desensitization was in 1908, at least a few years before the first published description of a diagnostic test for food allergy. It has taken almost 100 years for food allergy to move from passive management of avoidance to a more proactive approach including prevention and treatment. In parallel, this has been matched by recognition of eosinophil gastrointestinal diseases, which were first described in the 1980s (although eosinophilic esophagitis was itself described in 1978). Full-Text PDF Teleallergy: Where Have We Been and Where Are We Going?The Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewTelemedicine uptake in allergy/immunology was slow before the coronavirus disease 2019 pandemic, but has accelerated since. This review examines where telemedicine has been in allergy/immunology and where it is headed in the future. Focus is placed on patient, physician, and health care professional satisfaction with telemedicine, capacity to expand access to allergy/immunology care, cost considerations, the regulatory environment, and future applications of telemedicine including adherence monitoring, wearable biosensors, artificial intelligence, and machine learning addressed. Full-Text PDF Asthma Management in ChildrenThe Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewAsthma is a common, complex heterogeneous disease often beginning in early life and is characterized by reversible airflow obstruction. The phenotypic differences that exist in children with asthma may impact underlying comorbid conditions and pharmacologic treatment choices. Prenatal factors for increased risk of asthma could include maternal diet and the maternal microbiome. Evidence also suggests that postnatal microbial exposures and colonization contribute to the risk of allergic diseases and asthma. Full-Text PDF Urticaria and Angioedema: Understanding Complex Pathomechanisms to Facilitate Patient Communication, Disease Management, and Future TreatmentThe Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewChronic spontaneous urticaria (CSU) is primarily a T2-dominant disease with a complex genetic background. Skin mast cell activation can be induced not only via the IgE-FcεRI axis but also from several other distinct mechanisms, molecules, and receptors involved in CSU onset, persistence, and exacerbation. These include autoallergy, autoimmunity, central or peripheral neuroimmune dysregulation, activation of both extrinsic and intrinsic coagulation pathways, and microbial infections. Besides mast cells, recent reports suggest the active and direct involvement of basophils and eosinophils. Full-Text PDF Diversity, Equity, and Inclusion: A Decade of Progress?The Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewThe concepts of diversity, equity, and inclusion are fundamental and more recently heavily discussed within medicine, research, and the larger society. There is increasing awareness that diversity of thoughts, perspectives, and backgrounds yields stronger teams and more effective results. There is also increasing awareness that stark inequities from systemic, institutional, and individual levels exist that limit the baseline opportunities for many populations. To close disparity gaps, broad aspects of diversity and promoting equity are required and efforts must be inclusive of those most marginalized. Full-Text PDF Diagnosis and Assessment of the AsthmasThe Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewOptimizing asthma diagnosis is an essential part of global strategies to reduce the excessive illness burden from asthma. New understanding about how to address the complexity and heterogeneity of the different forms of asthma means that asthma diagnosis now requires a compound diagnostic approach and label. Eliciting the typical symptoms and abnormal physiology of variable airflow limitation permits the recognition of asthma, and the identification of further features, such as eosinophilic or type 2 inflammation, allows a compound diagnostic label of eosinophilic asthma. Full-Text PDF A Decade of Clinical Advances in Chronic Rhinosinusitis: 2012–2022The Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewThe field of chronic rhinosinusitis (CRS) is constantly evolving. In the past 10 years, key advancements in basic and translational research as well as clinical studies have improved our understanding and management of CRS. Notably, treatment options have expanded to include novel therapeutic drugs, devices, and surgical techniques. Assessments of patient symptoms and their impact on quality of life have become more standardized. Progress has also been made in both determining the true prevalence of CRS and recognizing comorbidities that can impact CRS severity. Full-Text PDF Value-Based, Cost-Effective Care: The Role of the Allergist-ImmunologistThe Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewAsthma and allergic disease impact millions of patients and are associated with high costs. Up to 30% of all medical care involves wasted spending. Across the spectrum of care provided by the allergist-immunologist, there are opportunities to improve value and reduce medical waste. Several examples highlight this reality. Evidence suggests that most patients may receive cost-effective care in the management of chronic spontaneous urticaria without the need for laboratory testing. For patients with asthma, although a single maintenance and reliever therapy approach may be cost-effective, insurance-mandated therapy changes are not, and may harm patients. Full-Text PDF Advances in the Understanding of Drug Hypersensitivity: 2012 Through 2022The Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewOver the last decade there have been key advances in understanding mechanisms, risk, and consequences of both true immunological drug hypersensitivity and unverified drug allergy labels that have changed clinical practice. This has been facilitated by the widespread adoption of electronic health records (EHRs). The vast majority of EHR drug allergy labels are unverified and cause significant morbidity from unnecessary avoidance of optimal drug therapy. There has also been significant movement in our understanding of mechanisms of drug hypersensitivity that, in addition to advancing our understanding of the pathogenesis of immediate and delayed reactions, have guided preventive efforts, diagnostic procedures, and clinical management. Full-Text PDF Asthma Management in AdultsThe Journal of Allergy and Clinical Immunology: In PracticeVol. 11Issue 1PreviewManagement of asthma in adults has advanced in the past 10 years. Central to these advances has been further clarification of type (T) 2 mechanisms of airway inflammation and utilization of T2 biomarkers, that is, eosinophils and fractional exhaled nitric oxide. In addition, epithelial cells are emerging as significant contributors to inflammation through generation of alarmins to initiate local injury as well as downstream pathways. Five new biologics, mepolizumab, benralizumab, reslizumab, dupilumab, and tezepelumab, were approved to join omalizumab and revolutionize severe asthma treatment. Full-Text PDF
Referência(s)